Research by DealForma

Decades of context backed by data from the DealForma database

Run your analyses better, in less time, with the newest database built for biopharma, medtech, and diagnostics.

Learn MoreSchedule Your Demo
Venture Activity In Global Healthcare & Life Sciences – 2023

Venture Activity In Global Healthcare & Life Sciences – 2023

An increase in down rounds in 2023 indicates a reassessment of valuations in VC. Challenges are expected to persist in the sector through the H1 of 2024, grappling with repercussions from previous excesses and a challenging fundraising environment. The initiation of a...

21,598

Licensing Deals

4,216

M&A

5,897

Other Deals

22,217

Funding Rounds

35,278

Company Profiles

27,588

Drug Sales Figures

All of this by stage, disease indication, modality, target

M&A In Global Healthcare & Life Sciences – 2023

M&A In Global Healthcare & Life Sciences – 2023

M&A's are resurging as deal values returned higher in the fourth quarter, though on fewer deals. Equipped with substantial resources, large pharmaceutical companies are inclined to pursue higher-value deals. Pfizer's acquisition of cancer specialist Seagen is a...

R&D Partnerships In Global Healthcare & Life Sciences In 2023

R&D Partnerships In Global Healthcare & Life Sciences In 2023

Biopharma and broader healthcare and life sciences R&D partnership activity continued its earlier slowdown, though not without major deals that marked the year in charts. SystImmune granted Bristol Myers Squibb exclusive rights to co-develop and co-commercialize...

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...

Cardiovascular Venture Activity Through Q3 2023

Cardiovascular Venture Activity Through Q3 2023

As we track cardiovascular venture activity in biopharma and medtech, companies like HeartFlow, Bitterroot Bio, DalCor Pharmaceuticals, Alleviant Medical, and Corteria Pharmaceuticals secured significant funding for groundbreaking advancements. HeartFlow, based in...

Neurology Venture Activity Through Q2 2023

Neurology Venture Activity Through Q2 2023

Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...

Biopharma IPO Watch: Therapeutics & Platforms

Biopharma IPO Watch: Therapeutics & Platforms

Biopharma IPO activity was still quiet through the second quarter 2023 with 3 companies going public on global exchanges for a total of $800 million. This follows 3 IPOs in the first quarter at $400 million. Among these IPOs, Laekna raised approximately $101 million...

M&A In Biopharma Therapeutics & Platforms – Q2 2023

M&A In Biopharma Therapeutics & Platforms – Q2 2023

Biopharma M&A activity in Q2 2023 picked up as the number of therapeutics and discovery platform company acquisitions tracked higher. The second quarter of 2023 saw 27 M&A deals for a total upfront of $27.4 billion or $28.1 billion when counting contingent...

Neurology M&A Snapshot Through Q2 2023

Neurology M&A Snapshot Through Q2 2023

We are looking at mergers and acquisitions in the neurology space through June 2023. As with the broader biopharma sector, neurology deal flow has been down since 2020. The year started with a decent number of billion-plus acquisitions in other biopharma therapeutic...

R&D Partnerships by TA – Autoimmune

R&D Partnerships by TA – Autoimmune

So far, 2023 has witnessed a mixed landscape for R&D partnerships in the autoimmune sector. While there were notable activities and collaborations, there was a decline in the number of deals and the overall value compared to previous years. This suggests a...

R&D Partnerships – Medtech – Q1 2023

R&D Partnerships – Medtech – Q1 2023

Medtech R&D partnerships play a significant role in driving innovation and advancements in healthcare. Medtech's various focus areas, such as medical devices, digital health solutions, and wearable technologies, saw active collaboration and investment, but deal...

Introducing: DealForma plus Tableau

Introducing: DealForma plus Tableau

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023 

Venture & IPO – Medtech – Q1 2023 

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...

M&A – Biopharma Therapeutics And Platforms – Q1 2023

M&A – Biopharma Therapeutics And Platforms – Q1 2023

Biopharma M&A started to in the first quarter of 2023 after a slow 2022. Major deals included Moderna's acquisition of OriCiro Genomics for $85 million, expanding Moderna's manufacturing capabilities for mRNA vaccines. Pfizer's blockbuster $43 billion acquisition...

Venture & IPO – Medtech

Venture & IPO – Medtech

Venture & IPO - Medtech As the demand for innovative medical technologies continues to grow, many entrepreneurs and investors are exploring ways to finance the development and commercialization of new MedTech products. Two popular options for raising capital in...

M&A – Medtech

M&A – Medtech

M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...

R&D Partnerships – Medtech

R&D Partnerships – Medtech

R&D PARTNERSHIPS – MEDTECH As we enter the first quarter of 2023, there is a persistent rise in R&D spending despite the mounting pressure to cut costs, reduce budgets and enhance profit margins. The life sciences sector anticipated an R&D expenditure of...

M&A – Biopharma Therapeutics And Platforms

M&A – Biopharma Therapeutics And Platforms

M&A – Biopharma Therapeutics And Platforms Mergers and Acquisitions are related concepts that refer to consolidating two or more companies into a single entity. In a merger, two or more companies come together to form a new company, while in an acquisition, one...